For more information on Awiqli\u00ae, clinical trial data, and prescribing information, please visit\u00a0Awiqli.com<\/a>. <\/p>\n About Awiqli\u00ae Awiqli\u00ae\u00a0is approved in the US, EU, and 13 additional countries, with market-specific indications for diabetes. <\/p>\n What is Awiqli\u00ae\u00a0(insulin icodec-abae) injection 700 units\/mL? <\/p>\n Prescription Awiqli\u00a0\u00ae\u00a0is a long-acting insulin (U-700) that is used to control high blood sugar in adults with type 2 diabetes mellitus <\/p>\n It is not known if Awiqli\u00ae\u00a0is safe and effective in children and adolescents <\/p>\n Awiqli\u00ae\u00a0is available in 1 concentration: U-700\u00a0 <\/p>\n Important Safety Information\u00a0 <\/p>\n Do not share your Awiqli\u00ae\u00a0FlexTouch\u00ae\u00a0pen or needles\u00a0with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them. <\/p>\n Make sure you use the right type and dose of insulin. Always check the label on your insulin pen before each injection to avoid mix-ups with Awiqli\u00ae\u00a0and other insulin products or injectable medicines used to treat diabetes. If you use another injectable medicine to treat your diabetes, pay close attention to how you select your Awiqli\u00ae\u00a0dosage. The dosage of Awiqli\u00ae\u00a0is different from other injectable medicines used to treat diabetes. <\/p>\n Always make sure that you select the correct dosage of your Awiqli\u00ae\u00a0FlexTouch\u00ae\u00a0pen as prescribed by your healthcare provider, to avoid dosing errors and accidental overdose. People who are blind or have vision problems should not use this pen without help from a person trained to use the pen. <\/p>\n Do not\u00a0dial the maximum single dosage (700 units) of your Awiqli\u00ae\u00a0FlexTouch\u00ae\u00a0pen, unless prescribed by your healthcare provider. <\/p>\n Do not use\u00a0a syringe to withdraw Awiqli\u00ae\u00a0from your pen. <\/p>\n Talk to your healthcare provider if you have any questions about how to correctly dose Awiqli\u00ae\u00a0FlexTouch\u00ae.\u00a0 <\/p>\n Who should not take Awiqli\u00ae? are having an episode of low blood sugar (hypoglycemia) <\/p>\n have an allergy to Awiqli\u00ae\u00a0or any of the ingredients in Awiqli\u00ae. See the full Patient Information for a complete listing of ingredients in Awiqli\u00ae <\/p>\n Before taking Awiqli\u00ae, tell your healthcare provider about all your medical conditions, including if you are: <\/p>\n have liver or kidney problems <\/p>\n take other medicines, especially ones called TZDs (thiazolidinediones) <\/p>\n have heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with Awiqli\u00ae <\/p>\n pregnant, planning to become pregnant, or are breastfeeding <\/p>\n taking new prescription or over-the-counter medicines, vitamins, or herbal supplements <\/p>\n Talk to your health care provider about low blood sugar and how to manage it. <\/p>\n How should I take Awiqli\u00ae\u00a0FlexTouch\u00ae? <\/p>\n Read the Instructions for Use\u00a0that come with your Awiqli\u00ae\u00a0FlexTouch\u00ae\u00a0pen <\/p>\n Your healthcare provider should show you how to use Awiqli\u00ae\u00a0FlexTouch\u00ae\u00a0pen before you use it for the first time <\/p>\n Take Awiqli\u00ae\u00a0exactly as your healthcare provider tells you to.\u00a0Do not do any conversion of your dose. The dose counter always shows the selected dose in units.\u00a0Awiqli\u00ae\u00a0FlexTouch\u00ae\u00a0pens are made to deliver your insulin dose in units <\/p>\n Know the type and strength of insulin you take.\u00a0Do not\u00a0change the type of insulin you take unless your health care provider tells you to. The amount of insulin and best time for you to take your insulin may need to change if you take different types of insulin <\/p>\n Inject Awiqli\u00ae\u00a0FlexTouch\u00ae\u00a01 time each week on any day of the week on the same day each week <\/p>\n If you need to change the day of the week, you may do so if your last dose has been at least\u00a04 days <\/p>\n If you have missed your dose, take your missed dose as soon as possible as long as it has been 4 days or less. Then continue the 1 time each week schedule 1 week from the day your missed dose was taken <\/p>\n If more than 4 days has passed, skip the missed dose and take your next Awiqli\u00ae\u00a0dose on your regularly scheduled day. <\/p>\n Check your blood sugar levels.\u00a0Ask your health care provider what your blood sugar levels should be and when you should check them <\/p>\n Never\u00a0inject Awiqli\u00ae\u00a0FlexTouch\u00ae\u00a0into a vein or muscle or use Awiqli\u00ae\u00a0in an infusion pump <\/p>\n Never\u00a0use a syringe to remove Awiqli\u00ae\u00a0from the FlexTouch\u00ae\u00a0pen <\/p>\n Do not dilute or mix Awiqli\u00ae\u00a0with any other insulin or solution <\/p>\n Awiqli\u00ae\u00a0FlexTouch\u00ae\u00a0can be injected under the skin (subcutaneously) of your upper legs (thighs), upper arms, or stomach area (abdomen) <\/p>\n Change (rotate) your injection sites within the area you choose with each dose\u00a0to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites. <\/p>\n Do not\u00a0use the exact same spot for each injection <\/p>\n Do not\u00a0inject where the skin has pits, is thickened, or has lumps <\/p>\n Do not\u00a0inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin <\/p>\n Keep Awiqli and all medicines out of the reach of children. <\/p>\n What should I avoid while taking\u00a0Awiqli\u00ae? <\/p>\n Do not\u00a0drive or operate heavy machinery, until you know how Awiqli\u00ae\u00a0affects you <\/p>\n Do not\u00a0drink alcohol or use prescription or over-the-counter medicines that contain alcohol <\/p>\n What are the possible side effects of\u00a0Awiqli\u00ae? <\/p>\n Awiqli\u00ae\u00a0may cause serious side effects that can be life-threatening, including: <\/p>\n Low blood sugar (hypoglycemia).\u00a0Signs and symptoms that may indicate low blood sugar include: dizziness or light-headedness, sweating, confusion, fast heartbeat, blurred vision, slurred speech, shakiness, anxiety, irritability, mood changes, hunger and headache <\/p>\n Severe allergic reactions (whole body reaction).\u00a0Stop using Awiqli and get medical help right away, if you have any of these signs or symptoms of a severe allergic reaction: a rash over you whole body, trouble breathing, a fast heartbeat or sweating <\/p>\n Low potassium in your blood (hypokalemia) <\/p>\n Heart failure\u00a0in some people if taken with thiazolidinediones (TZDs). This can happen even if you have never had heart failure or heart problems. If you already have heart failure, it may get worse while you take TZDs with Awiqli\u00ae. Tell your health care provider if you have any new or worse symptoms of heart failure including shortness of breath, tiredness, swelling of your ankles or feet, and sudden weight gain <\/p>\n Your insulin dose may need to change because of\u00a0change in level of physical activity or exercise, increased stress, change in diet, weight gain or loss, or illness <\/p>\n Common side effects may include:\u00a0hypoglycemia, serious allergic reactions (whole body reactions), reactions at the injection site, skin thickening or pits at the injection site (lipodystrophy), itching, rash, swelling of your hands and feet, and weight gain. <\/p>\n Get emergency medical help if you\u00a0have trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion <\/p>\n These are not all the possible side effects of Awiqli\u00ae. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 <\/p>\n Please click here for the full\u00a0Prescribing Information<\/a>. <\/p>\n About Novo Nordisk _______________________ <\/p>\n References <\/p>\n Awiqli\u00ae\u00a0(insulin icodec-abae) [package insert]. Plainsboro, NJ: Novo Nordisk Inc. <\/p>\n Jude E, Malecki M, Huelgas R, et al. Expert panel guidance and narrative review of treatment simplification of complex insulin regimens to improve outcomes in type 2 diabetes. Diabetes Ther.\u00a013, 619\u2013634 (2022). https:\/\/doi.org\/10.1007\/s13300-022-01222-2 <\/p>\n Rosenstock J, Gowda A, Liang B. Weekly icodec versus daily glargine U100 in type 2\u00a0diabetes without previous insulin. N Engl J Med. 2023;389(16):1533. doi:10.1056\/NEJMc2310221 <\/p>\n Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023 https:\/\/doi.org\/10.1016\/S2213-8587(23)00093-1<\/a> <\/p>\n Lingvay I, Asong M, Desouza C, et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial. JAMA. 2023;330(3):228\u2013237. doi:10.1001\/jama.2023.11313 <\/p>\n Mathieu C,\u00a0\u00c1sbj\u00f6rnsd\u00f3ttir B, Bajaj H, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. 2023 https:\/\/doi.org\/10.1016\/S0140-6736(23)00520-2 <\/p>\n Awiqli\u00ae\u00a0and FlexTouch\u00ae\u00a0Pen are registered trademarks of Novo Nordisk A\/S. View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/novo-nordisks-awiqli-the-first-once-weekly-basal-insulin-for-adults-with-type-2-diabetes-now-available-in-the-us-302847645.html<\/a> <\/p>\n
Awiqli\u00ae\u00a0(insulin icodec-abae) injection 700 units\/mL is a prescription medicine and is the first and only FDA-approved once-weekly basal insulin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.1\u00a0Awiqli\u00ae\u00a0is designed as an alternative to daily basal insulin and its approval is supported by the ONWARDS clinical program, which evaluated its efficacy and safety across diverse adult populations living with type 2 diabetes.3-6\u00a0Awiqli\u00ae\u00a0is administered once-weekly on the same day each week using the Awiqli\u00ae\u00a0FlexTouch\u00ae\u00a0pen.1 <\/p>\n
Do not take Awiqli\u00ae\u00a0if you: <\/p>\n
Novo Nordisk is a leading global healthcare company\u00a0that’s\u00a0been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We\u00a0remain\u00a0steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in\u202fNew Jersey and employs approximately 10,000 people throughout the country across more than 10 manufacturing, R&D and corporate locations in seven states plus\u202fWashington DC. For more information, visit\u202fnovonordisk-us.com<\/a>,\u202fFacebook<\/a>,\u202fInstagram<\/a>, and\u202fX<\/a>. <\/p>\n
Novo Nordisk is a registered trademark of Novo Nordisk A\/S.
\u00a9 2026 Novo Nordisk All rights reserved. US26AWQ00068 August 2026 <\/p>\n<\/a> Novo Logo
<\/a> Cision <\/p>\n